Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul;33(6):e22908.
doi: 10.1002/jcla.22908. Epub 2019 May 20.

Clinical significance of BPI-ANCA detecting in COPD patients with Pseudomonas aeruginosa colonization

Yongjian Tian  1 , Tingting Zeng  1 , Liming Tan  1 , Yang Wu  1 , Jianlin Yu  1 , Jiayi Huang  1 , Zihuang Pei  1
Affiliations

Clinical significance of BPI-ANCA detecting in COPD patients with Pseudomonas aeruginosa colonization

Yongjian Tian et al. J Clin Lab Anal. 2019 Jul.

Abstract

Background: Antineutrophil cytoplasmic autoantibodies against neutrophil granule bactericidal/permeability-increasing protein (BPI-ANCA) has been found in many inflammatory diseases, such as COPD, which can reduce the killing effect of BPI on Gram-negative bacteria. This study was aimed to assess the clinical significance of BPI-ANCA detecting in COPD patients with Pseudomonas aeruginosa (P aeruginosa) colonization.

Methods: A total of 216 COPD patients with lung P aeruginosa colonization, 244 patients with P aeruginosa infection from June 2015 to June 2018, and 100 healthy individuals were included. Serum BPI-ANCA, tumor necrosis factor (TNF)-α, and interleukin (IL)-6 and IL-1β levels were detected by ELISA, and the lung function of the patients was measured at stable clinical stages. Patients with COPD were grouped according to BPI-ANCA detection and GOLD criteria, and serum TNF-α, IL-6, and IL-1β levels and indices reflecting lung function were compared and analyzed between groups.

Results: Positive rate of BPI-ANCA in COPD patients with P aeruginosa colonization was 48.15%; and compared with BPI-ANCA(-) group, FEV1 %pred and FEV1 /FVC(%) in BPI-ANCA(+) patients were significantly decreased, while TNF-α, IL-6, and IL-1β levels were elevated. There were 31.73% and 36.54% BPI-ANCA(+) patients with severe and very severe airflow limitation, respectively, which was significantly higher than that in the BPI-ANCA(-) group. FEV1 %pred and FEV1 /FVC(%) were negatively correlated with TNF-α, IL-6, IL-1β, and NEU%. C-reactive protein (CRP) was negatively correlated with FEV1 %pred, yet not significantly correlated with FEV1 /FVC(%).

Conclusion: BPI-ANCA positivity is associated with inflammatory status in COPD patients with pulmonary P aeruginosa colonization and can be used as a potential biomarker assessing disease severity.

Keywords: Pseudomonas aeruginosa; antineutrophil cytoplasm autoantibodies; bactericidal/permeability-increasing protein; chronic obstructive pulmonary disease; cytokines.

PubMed Disclaimer

Conflict of interest statement

All authors declared that they have no conflict of interests.

Figures

Figure 1
Figure 1
Flowchart of participants' inclusion and exclusion criteria
See this image and copyright information in PMC

References

    1. Hassett DJ, Borchers MT, Panos RJ. Chronic obstructive pulmonary disease (COPD): evaluation from clinical, immunological and bacterial pathogenesis perspectives. J Microbiol. 2014;52:211‐226. - PubMed
    1. Choi J, Oh JY, Lee YS, et al. Pseudomonas aeruginosa infection increases the readmission rate of COPD patients. Int J Chron Obstruct Pulmon Dis. 2018;13:3077‐3083. - PMC - PubMed
    1. Schultz H, Weiss JP. The bactericidal/permeability‐increasing protein (BPI) in infection and inflammatory disease. Clin Chim Acta. 2007;384:12‐23. - PMC - PubMed
    1. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347‐365. - PubMed
    1. Canton R, Cobos N, de Gracia J, et al. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect. 2005;11:690‐703. - PubMed